Open AccessMucosal Cytokine Profiles After Induction Therapy With Granulocyte/Monocyte Apheresis in New‐onset Inflammatory Colitis
Author(s) -
Rolandsdotter Helena,
JönssonVidesäter Kerstin,
L. Fagerberg Ulrika,
Eberhardson Michael,
Finkel Yigael
Publication year - 2018
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0000000000001735
Subject(s) - medicine , apheresis , monocyte , granulocyte , cytokine , colitis , immunology , granulocyte macrophage colony stimulating factor , platelet
Granulocyte/monocyte apheresis (GMA) selectively removes circulating granulocytes and monocytes; important producers of proinflammatory cytokines. Seven children with new‐onset inflammatory bowel disease (IBD) colitis were treated with GMA together with mesalazine, and had significant decreases in Pediatric UC Activity Index ( P = 0.018) and Mayo endoscopic score ( P = 0.013). We investigated the colonic mucosal cytokine profiles (analyzed with real‐time polymerase chain reaction), before and after induction treatment, and in 6 non‐IBD controls. Significant decreases were seen in Colony Stimulating Factor 2 ( P = 0.018), tumor necrosis factor‐α ( P = 0.028), interleukin (IL)‐23α ( P = 0.043), IL‐1β ( P = 0.028), IL‐36γ ( P = 0.018), IL‐10 ( P = 0.028), and transforming growth factor beta 1 ( P = 0.043) after treatment. In 6 non‐IBD controls there were significantly lower levels of IL‐12β ( P = 0.023) and IL‐23α ( P = 0.046) compared to the patients with IBD at onset, and IL‐22 ( P = 0.088) and IL‐36γ ( P = 0.062) showed lower values without reaching significant differences. We speculate that the decreases in colonic mucosal cytokine profiles after treatment may explain the observed clinical efficacy in the GMA‐treated children with IBD.